



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Timothy A. Stewart et al.

Serial No.: 09/522,342

Filed: March 9, 2000

For: Fibroblast Growth Factor-19 (FGF-

19) Nucleic Acids and Polypeptides

and Methods of Use for the

Treatment of Obesity

Group Art Unit: 1647

Examiner: SAUOD, C.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

. 20231 011

November 19, 2001

Aida Guiam

PRELIMINARY AMENDMENT

BOX: NON-FEE AMENDMENT Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Prior to the examination of this application on its merits, please amend the application as follows:

In the Specification:

Please insert as the first sentence of the specification following the title, the following:

--This application is a continuation-in-part application (filed under 35 U.S.C.§120) which application claims priority to U.S. Provisional Application No. 60/066,840, filed November 25, 1997, to which U.S. Provisional Application claims priority under 35 U.S.C. §119; and to International PCT Application No. PCT/US98/25190, filed November 25, 1998, and U.S. Patent Application Nos.: 09/158,342, filed September 21, 1998 and 09/284,663, filed April 15, 1999, to which International PCT Application and U.S. Patent Applications claim priority under 35 U.S.C. §120; the entire disclosures of which are hereby incorporated by reference in their entireties.--

REMARKS

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."